Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model

International Journal of Cancer

Volumn 114, Issue 1, 2005, Pages 124-130

  Chun, Eunyoung ^a   Han, Cheol Kyu ^b   Yoon, Jeong Hyeok ^b   Sim, Tae Bo ^b   Kim, Yoon Keun ^c   Lee, Ki Young ^c,d  

^a Mogam Biotechnology Research Institute   (South Korea)

^b IDR Research Institute   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Endothelial cells; Tumor immunity

Indexed keywords

ANGIOGENESIS INHIBITOR; CKD 732; CYCLIN DEPENDENT KINASE INHIBITOR 1; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IDR 803; IDR 804; IDR 805; METHIONYL AMINOPEPTIDASE; METHIONYL AMINOPEPTIDASE 2; METHIONYL AMINOPEPTIDASE 2 INHIBITOR; PEPTIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MITOSIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR XENOGRAFT; UMBILICAL VEIN;

AMINOPEPTIDASES; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CINNAMATES; CYCLOHEXANES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EPOXY COMPOUNDS; FATTY ACIDS, UNSATURATED; HUMANS; LIVER NEOPLASMS; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; TRANSPLANTATION, HETEROLOGOUS; UMBILICAL VEINS;

EID: 13244265583     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20687     Document Type: Article

References (32)

1. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;23:442-7.
2. Risau W. Angiogenic growth factors. Prog Growth Factor Res 1990;2:71-9.
3. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333-46.
4. Swerlick RA. Angiogenesis. J Dermatol 1995;22:845-52.
5. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
7. Griffioen AW, Barendsz-Janson AF, Mayo KH, Hillen HF. Angiogenesis, a target for tumor therapy. J Lab Clin Med 1998;132:363-8.
8. Jekunen AP, Kairemo KJ. Inhibition of malignant angiogenesis. Cancer Treat Rev 1997;23:263-86.
9. Kern FG, Lippman ME. The role of angiogenic growth factors in breast cancer progression. Cancer Metastasis Rev 1996;15:213-9.
10. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-8.
11. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990;248:1408-10.
12. Muller G, Behrens J, Nussbaumer U, Bohlen P, Birchmeier W. Inhibitory action of transforming growth factor beta on endothelial cells. Proc Natl Acad Sci USA 1987;84:5600-4.
13. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8.
14. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990;82:848-53.
15. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
16. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997;4:461-71.
17. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997;94:6099-103.
18. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J 2001;15:1044-53.
19. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-69.
20. Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 2001;61:3450-7.
21. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246-53.
22. Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, Penn M, Chen CT, Mori K, Melia M, Phipps S, Moffat D, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001;159:313-20.
23. MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, Liang H, Holland-Linn J, Chen DH, Sim BK. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-6.
24. Han CK, Ahn SK, Choi NS, Hong RK, Moon SK, Chun HS, Lee SJ, Kim JW, Hong CI, Kim D, Yoon JH, No KT. Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2. Bioorg Med Chem Lett 2000;10:39-43.
25. + T cells in xenografted nude mice. J Immunol 2003;170:1183-90.
26. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998;282:1324-7.
27. Lee HS, Choi WK, Son HJ, Lee SS, Kim JK, Ahn SK, Hong CI, Min HK, Kim M, Myung SW. Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. Arch Pharm Res 2004;27:265-72.
28. Kim JH, Lee SK, Ki MH, Choi WK, Ahn SK, Shin HJ, Hong CI. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin. Int J Pharm 2004;272:79-89.
29. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 2000;97:12782-7.
30. Huang J, Frischer JS, New T, Kim ES, Serur A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, et al. TNP-470 promotes initial vascular sprouting in xenograft tumors. Mol Cancer Ther 2004;3:335-43.
31. Varshavsky A, Turner G, Du F, Xie Y. Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway. Biol Chem 2000;381:779-89.
32. Varshavsky A. The N-end rule pathway of protein degradation. Genes Cells 1997;2:13-28.